Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:56:21 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:AFMD - AFFIMED N V - http://www.affimed.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AFMD - Q5.05.00·6.300.15.42+0.112.182.34173705.42  5.51  5.1011.10  2.23516:00:01Apr 2415 min RT 2¢

Recent Trades - Last 10 of 370
Time ETExPriceChangeVolume
16:00:01Q5.420.1211
16:00:01Q5.420.1212
16:00:01Q5.420.1212
16:00:01Q5.420.1211
16:00:01Q5.420.1212
16:00:01Q5.420.1212
16:00:01Q5.420.1212
16:00:01Q5.420.124
16:00:01Q5.420.128
16:00:01Q5.420.11100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 04:05U:AFMDNews ReleaseAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
2024-03-28 06:30U:AFMDNews ReleaseAffimed Reports 2023 Financial Results and Operational Progress
2024-03-21 06:30U:AFMDNews ReleaseAffimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
2024-03-06 06:30U:AFMDNews ReleaseAffimed Announces 1-for-10 Reverse Stock Split
2024-01-08 16:05U:AFMDNews ReleaseAffimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
2024-01-08 08:00U:AFMDNews ReleaseAffimed Announces Leadership Change and ‚  Organizational Restructuring
2024-01-03 06:30U:AFMDNews ReleaseAffimed Announces Sale of Wholly-Owned Subsidiary AbCheck
2023-12-11 06:02U:AFMDNews ReleaseAffimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
2023-12-11 06:00U:AFMDNews ReleaseAffimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
2023-12-04 06:30U:AFMDNews ReleaseAffimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
2023-11-14 06:30U:AFMDNews ReleaseAffimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
2023-11-09 06:30U:AFMDNews ReleaseAffimed Announces Acimtamig as International Nonproprietary Name for AFM13
2023-11-07 06:30U:AFMDNews ReleaseAffimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
2023-11-03 12:05U:AFMDNews ReleaseAffimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
2023-11-02 09:05U:AFMDNews ReleaseAffimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
2023-11-01 06:30U:AFMDNews ReleaseAffimed to Participate in Upcoming Investor Conferences
2023-10-04 06:30U:AFMDNews ReleaseAffimed Announces Listing Transfer to Nasdaq Capital Markets
2023-09-27 09:05U:AFMDNews ReleaseAffimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
2023-09-21 06:30U:AFMDNews ReleaseAffimed to Present at the Cantor Global Healthcare Conference 2023
2023-09-12 06:30U:AFMDNews ReleaseAffimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK ‚ ® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma